Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer.
about
Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancerRole of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic reviewTime-dependent endpoints as predictors of overall survival in multiple myelomaIndividual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.Metabolic burden measured by (18)f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancerSurrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancerIdentification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsMagnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapyClinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Clinical significance of post-progression survival in lung cancerProgression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer.Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy.Factors associated with long-term survival of patients with advanced non-small cell lung cancer.Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
P2860
Q26829939-4351781E-2DC4-4D95-8F33-FB9F95AC23D3Q27025724-372A5814-6D67-408D-ABE7-65A96DEE3093Q30538040-02D1B1CF-C4C1-456A-889B-035DE55A7158Q30833179-91F1D363-D426-438B-A1B4-94A3C13DF5E1Q33619243-3D3403B0-C6F1-4FF4-B7C7-62F550BB00F0Q33933021-C2B2D82B-AC53-4894-AB65-CF676E714EBEQ34094103-29D4AD22-6392-4057-8CF9-3EE857B9BED2Q34374754-956EFC78-81BC-4E0B-BF12-694694333952Q34866341-735DF59A-C3FD-4BB1-8D50-1EF48C3DA288Q35004750-B3245BFD-921A-44E2-AA12-F878E5A4E3D6Q35578537-FC544F83-6EF7-45D6-ADBE-AD318E91626EQ36490413-93C0228C-3F38-49E5-864E-28D5167DD073Q37389608-085264F8-E16E-490D-8CE2-64147ECAE8C0Q38259501-D9D96E4E-D7EB-418F-90F2-A07016E5C853Q38669447-E57C6E47-8F6C-46CB-855A-C221314AA7A4Q38720644-DAC60101-8012-4300-B830-D7DEBA5DCBF5Q38852314-2CD13D5A-D54B-48DD-9C3A-8F0D646F79A3Q39572955-1805F1B4-DE30-4E4E-92C6-B804AA761A73Q39778923-F392289B-3B0B-4C9F-B30B-AF83DE393245Q42852367-7E468BED-74A0-4F84-8E81-654386E8DA7AQ43518078-51840E1D-4F86-4E25-BD0A-27525A823C63Q43870660-7308F683-ACB3-4978-98E0-6A126C9475EBQ44109504-8ECABB9B-B284-4626-AB22-C6EAB4660E91Q51088833-535EA5B8-0B3B-4854-8209-7ADCD3E4BC1DQ53717818-533C1A58-44B7-49E6-865D-03E414899373Q58769992-6E2B9C6B-3DFE-48DF-896D-F6EA250D6217
P2860
Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Time to progression as a surro ...... ed non-small cell lung cancer.
@en
Time to progression as a surro ...... ed non-small cell lung cancer.
@nl
type
label
Time to progression as a surro ...... ed non-small cell lung cancer.
@en
Time to progression as a surro ...... ed non-small cell lung cancer.
@nl
prefLabel
Time to progression as a surro ...... ed non-small cell lung cancer.
@en
Time to progression as a surro ...... ed non-small cell lung cancer.
@nl
P2093
P50
P1476
Time to progression as a surro ...... ed non-small cell lung cancer.
@en
P2093
Katsuyuki Hotta
Masahiro Tabata
Nagio Takigawa
Yoshiro Fujiwara
P304
P356
10.1097/JTO.0B013E3181989BD2
P577
2009-03-01T00:00:00Z